---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026760"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:37:18.437466+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arcus ARC-7 Phase 2: domvanalimab doublet cuts progression risk 45% vs. zimberelimab

## Summary
- Median PFS: doublet 12.0 mo, triplet 10.9 mo vs. monotherapy 5.4 mo (HR 0.55 and 0.65).
- Confirmed ORR: doublet 41%, triplet 40% vs. monotherapy 27% in PD-L1≥50% 1L NSCLC.
- Six-month PFS rate: doublet 65%, triplet 63% vs. monotherapy 43%; median follow-up ~12 mo.
- No new safety signals; Grade≥3 AEs: doublet 47%, triplet 52% vs. monotherapy 58%.
- Trial continues to monitor overall survival; data cutoff Aug 31, 2022 (n=149 safety, 133 efficacy).

## SEC filing metadata
- accession: 0000950170-22-026760
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000095017022026760/0000950170-22-026760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000095017022026760/rcus-20221219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026760
- JSON: https://secwatch.observer/filing/0000950170-22-026760.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.